chloroquine and derivatives - for COVID-19 method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

clinical improvement 1.34 [0.96, 1.87]> 118%4 studies (4 / -)96.0 %highnot evaluable lowcrucial-
clinical improvement (14-day) 1.36 [0.95, 1.95]> 10%2 studies (2 / -)95.2 %some concernnot evaluable moderatecrucial-
clinical improvement (time to event analysis only) 1.01 [0.59, 1.74]> 10%1 study (1 / -)51.7 %highnot evaluable lowcrucial-
clinical worsening 0.58 [0.07, 5.05]< 158%2 studies (2 / -)68.6 %highnot evaluable lowcrucial-
deaths 1.11 [0.98, 1.26]< 10%3 studies (3 / -)4.9 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 1.11 [0.98, 1.26]< 10%1 study (1 / -)5.2 %some concernnot evaluable moderatecrucial-
PCR-negative conversion 0.83 [0.57, 1.21]> 10%2 studies (2 / -)17.2 %highnot evaluable lowimportant-
PCR-negative conversion (14-day) 1.09 [0.95, 1.26]> 10%1 study (1 / -)88.2 %some concernnot evaluable moderateimportant-
PCR-negative conversion (7-day) 1.12 [0.58, 2.19]> 10%2 studies (2 / -)63.2 %some concernnot evaluable moderateimportant-
PCR-negative conversion (time to event analysis only) 0.85 [0.58, 1.23]> 10%1 study (1 / -)19.3 %highnot evaluable lowimportant-
radiologic improvement (14-day) 1.33 [0.94, 1.88]> 10%1 study (1 / -)94.7 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 3.43 [1.10, 10.70]> 10%1 study (1 / -)98.3 %highnot evaluable lowimportant-
radiologic progression 0.57 [0.13, 2.50]< 10%1 study (1 / -)77.1 %some concernnot evaluable moderateimportant-

OLD safety endpoints 00

diarrhea and abnormal liver function 1.45 [0.26, 8.01]< 10%1 study (1 / -)33.4 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 3 pathologies: 87,95,94,90,91,97 95, 97, 90